Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons (vol 9, pg 1491, 2018)

被引：1
|
作者：
Balijepalli, Chakrapani [1 ]
Shirali, Rohan [1 ]
Kandaswamy, Prashanth [2 ]
Ustyugova, Anastasia [2 ]
Pfarr, Egon [2 ]
Lund, Soren S. [2 ]
Druyts, Eric [1 ]
机构：
[1] Precis Hlth Econ, Vancouver, BC, Canada
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
DIABETES THERAPY | 2019年 / 10卷 / 01期
关键词：
D O I：
10.1007/s13300-018-0543-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The authors have updated Fig. 3 which was incorrectly published in the original publication.
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [1] Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
    Balijepalli, Chakrapani
    Shirali, Rohan
    Kandaswamy, Prashanth
    Ustyugova, Anastasia
    Pfarr, Egon
    Lund, Soren S.
    Druyts, Eric
    DIABETES THERAPY, 2018, 9 (04) : 1491 - 1500
  • [2] Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
    Chakrapani Balijepalli
    Rohan Shirali
    Prashanth Kandaswamy
    Anastasia Ustyugova
    Egon Pfarr
    Søren S. Lund
    Eric Druyts
    Diabetes Therapy, 2018, 9 : 1491 - 1500
  • [3] Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
    Chakrapani Balijepalli
    Rohan Shirali
    Prashanth Kandaswamy
    Anastasia Ustyugova
    Egon Pfarr
    Søren S. Lund
    Eric Druyts
    Diabetes Therapy, 2019, 10 : 325 - 326
  • [4] CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS
    Balijepalli, C.
    Shirali, R.
    Kandaswamy, P.
    Ustyugova, A., V
    Pfarr, E.
    Lund, S. S.
    Druyts, E.
    VALUE IN HEALTH, 2018, 21 : S121 - S121
  • [5] Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2015, 4 : 19 - 24
  • [6] Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2015, 4 (06): : 238 - 242
  • [7] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
    不详
    JOURNAL OF DIABETES, 2009, 1 (01) : 6 - 7
  • [8] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
    Richter, B.
    Bandeira-Echtler, E.
    Bergerhoff, K.
    Lerch, C. L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [9] A META-ANALYSIS OF EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 [DPP-4] INHIBITORS IN TYPE 2 DIABETES
    Park, H.
    Park, C.
    Kim, Y.
    Rascati, K. L.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [10] EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, Masanori
    Okada, Kazuyoshi
    Oikawa, Osamu
    Maruyama, Noriaki
    Furukawa, Tetsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 216 - 216
12345